Get the Stockscreener App
4.21
0.48%
0.02
Omeros Corporation stock is traded at $4.21, with a volume of 111.92K.
It is up +0.48% in the last 24 hours and up +1.45% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$4.19
Open:
$4.3
24h Volume:
111.92K
Relative Volume:
0.10
Market Cap:
$286.52M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-2.2394
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-8.68%
1M Performance:
+1.45%
6M Performance:
-37.44%
1Y Performance:
+7.40%
1-Day Range:
$4.20
$4.30
1-Week Range:
$4.15
$4.69
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
4.21 | 285.15M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.82 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.48 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.00 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.73 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Wealth Enhancement Advisory Services LLC Has $84,000 Stock Holdings in Omeros Corporation $OMER - Defense World
Quantitative breakdown of Omeros Corporation recent move2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Can Omeros Corporation stock sustain institutional interestBull Run & Capital Efficient Trading Techniques - newser.com
Omeros (NASDAQ:OMER) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What institutional flow reveals about Omeros CorporationTrade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Lobbying Update: $30,000 of OMEROS CORPORATION lobbying was just disclosed - Quiver Quantitative
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
How to build a dashboard for Omeros Corporation stockWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Retail investors who hold 53% of Omeros Corporation (NASDAQ:OMER) gained 10%, institutions profited as well - simplywall.st
Mydriasis Market: Epidemiology, Therapies, and Key Players include Théa Laboratories, Omeros Corporation, Ocuphire Pharma. - Barchart.com
Intraday pattern recognizer results for Omeros CorporationJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Omeros Corporation stock trend forecast2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
What moving averages say about Omeros CorporationMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Is Omeros Corporation a good long term investmentInsider Buying Signals & Build Wealth With Strategy - earlytimes.in
Using RSI to spot recovery in Omeros CorporationAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH - TipRanks
What analysts say about Omeros Corporation stockTechnical Breakout Signals & Receive Monthly Expert Trading Blueprints - earlytimes.in
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Will Omeros Corporation price bounce be sustainablePortfolio Profit Report & Long-Term Growth Plans - newser.com
Omeros (NASDAQ:OMER) Upgraded at Wall Street Zen - MarketBeat
Goldman Sachs Group Inc. Sells 30,445 Shares of Omeros Corporation $OMER - Defense World
Fund Flows: Will Omeros Corporation benefit from rising consumer demandWeekly Gains Report & Risk Managed Investment Strategies - خودرو بانک
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Stock Rating Upgraded by Wall Street Zen - Defense World
Omeros Corporation stock trendline breakdownRecession Risk & Accurate Buy Signal Notifications - newser.com
Will Omeros Corporation see short term momentumMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
Real time pattern detection on Omeros Corporation stock2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
Full technical analysis of Omeros Corporation stockPortfolio Growth Summary & Weekly High Return Stock Forecasts - newser.com
Rally Mode: Will GRMN stock go up in YEAR2025 Macro Impact & Weekly Return Optimization Plans - khodrobank.com
Identifying reversal signals in Omeros CorporationMarket Trend Review & Precise Buy Zone Tips - newser.com
Trading Action: Can Omeros Corporation deliver alphaEntry Point & Community Verified Swing Trade Signals - خودرو بانک
Using data tools to time your Omeros Corporation exitWeekly Stock Summary & Daily Volume Surge Signals - newser.com
How to track smart money flows in Omeros CorporationVolume Spike & Fast Exit Strategy with Risk Control - newser.com
Growth Value: Is Expand Energy Corporation Equity Warrant a stock for growth or value investorsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - خودرو بانک
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):